Stocks News

LAST PRICE
1.1400
TODAY'S CHANGE (%)
Trending Up0.0300 (2.7027%)

Bid / Lots
1.1200/ 10
Ask / Lots
1.1400/ 3
Open / Previous Close
1.1100 / 1.1100
Day Range
Low 1.0900
High 1.1500
52 Week Range
Low 0.6800
High 4.1000
Volume
129,110
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 12, 2024
- -- Earnings Flash (OVID) OVID THERAPEUTICS Reports Q3 Revenue $173,000, from 8:05AM ET on Tuesday Nov 12, 2024 by MT Newswires
  8:05AM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: OVID
  08:05 AM EST, 11/12/2024 (MT Newswires) -- ...
- *DJ Ovid Therapeutics 3Q Loss/Shr 20c >OVID, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: OVID
- Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: OVID
  
  Third Quarter 2024 Financial Results
  -- Cash, cash equivalents and marketable securities as of September 30, 2024, totaled $62.7 million. -- Revenues from royalty agreements were $173,000 for the third quarter ended September 30, 2024, as compared to $109,000 in the same period in 2023. -- Research and development expenses were $7.9 million for the third quarter ended September 30, 2024, compared to $5.3 million in the same period in 2023. The increase is related to the advancement of Ovid's clinical and preclinical pipeline programs as described above. -- General and administrative expenses were $5.5 million for the third quarter ended September 30, 2024, as compared to $6.8 million for the same period in 2023. The decrease was driven by the previous organizational restructuring and related cost-reduction efforts. -- Total operating expenses were $13.4 million for the third quarter ended September 30, 2024, as compared to $12.1 million for the same period last year. -- Ovid reported a net loss of $14.0 million, or basic and diluted net loss per share attributable to common stockholders of $0.20, for the third quarter of 2024, as compared to a net loss of $11.3 million, or basic and diluted net loss per share attributable to common stockholders of $0.16, for the same period in 2023.
Oct 31, 2024
- Ovid Therapeutics to Host Investor Event, from 8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: OVID
  
  Ovid Therapeutics to Host Investor Event
  
  KCC2 Download Day on Wednesday, November 13, 2024
  
  NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that it will host an investor event focused on its portfolio of direct potassium chloride co-transporter 2 (KCC2) activators on Wednesday, November 13, 2024. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30 to 11:30 am ET and will be webcast simultaneously.

Nov 27, 2024
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAF, ATSG, ENTO, AVTE on Behalf of Shareholders, from 7:00AM ET on Wednesday Nov 27, 2024 by PR Newswire
  7:00AM ET on Wednesday Nov 27, 2024 by PR Newswire
  Companies Mentioned: ENTO, ATSG, STAF, AVTE
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAF, ATSG, ENTO, AVTE on Behalf of Shareholders, from 7:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
  7:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
  Companies Mentioned: ENTO, ATSG, STAF, AVTE
Nov 26, 2024
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Poseida Therapeutics, Inc. (Nasdaq -- PSTX), Air Transport Services Group, Inc. (Nasdaq-- ATSG), Micropac Industries, Inc. (OTC - MPAD), Aerovate Therapeutics, Inc. (Nasdaq - AVTE), from 3:45PM ET on Tuesday Nov 26, 2024 by Dow Jones
  3:45PM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: MPAD, ATSG, PSTX, AVTE
- ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference, from 8:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  8:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: ALXO
Nov 14, 2024
- Press Release: ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: ALXO
- ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: ALXO
Nov 13, 2024
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE, BMTX, PFIE, ALTR on Behalf of Shareholders, from 4:31PM ET on Wednesday Nov 13, 2024 by Dow Jones
  4:31PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: ALTR, BMTX, PFIE, AVTE
- $HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of BMTX, AVTE, ALTR and PFIE, from 3:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
  3:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: ALTR, BMTX, AVTE
- DJ BioAtla Cut to Neutral From Buy by HC Wainwright & Co., from 8:12AM ET on Wednesday Nov 13, 2024 by Dow Jones
  8:12AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: BCAB
- HC Wainwright Downgrades BioAtla to Neutral From Buy, from 7:43AM ET on Wednesday Nov 13, 2024 by MT Newswires
  7:43AM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: BCAB

Ovid Therapeutics Inc
NASDAQ:OVIDUnited States

Search Criteria

Nov 12, 2024

-- Earnings Flash (OVID) OVID THERAPEUTICS Reports Q3 Revenue $173,000, from 8:05AM ET on Tuesday Nov 12, 2024 by MT Newswires

*DJ Ovid Therapeutics 3Q Loss/Shr 20c >OVID, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

Oct 31, 2024

Ovid Therapeutics to Host Investor Event, from 8:00AM ET on Thursday Oct 31, 2024 by Dow Jones

Peers Headlines

Nov 27, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAF, ATSG, ENTO, AVTE on Behalf of Shareholders, from 7:00AM ET on Wednesday Nov 27, 2024 by PR Newswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAF, ATSG, ENTO, AVTE on Behalf of Shareholders, from 7:00AM ET on Wednesday Nov 27, 2024 by Dow Jones

Nov 26, 2024

ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference, from 8:00AM ET on Tuesday Nov 26, 2024 by Dow Jones

Nov 14, 2024

Press Release: ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 13, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE, BMTX, PFIE, ALTR on Behalf of Shareholders, from 4:31PM ET on Wednesday Nov 13, 2024 by Dow Jones

$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of BMTX, AVTE, ALTR and PFIE, from 3:01PM ET on Wednesday Nov 13, 2024 by Dow Jones

DJ BioAtla Cut to Neutral From Buy by HC Wainwright & Co., from 8:12AM ET on Wednesday Nov 13, 2024 by Dow Jones

HC Wainwright Downgrades BioAtla to Neutral From Buy, from 7:43AM ET on Wednesday Nov 13, 2024 by MT Newswires